Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in glaucoma therapeutics.

Abbot F Clark1, Iok-Hou Pang

  • 1Glaucoma Research R2-41, Alcon Research Ltd, 6201 South Freeway, Fort Worth, Texas 76134, USA. abe.clark@alconlabs.com

Expert Opinion on Emerging Drugs
|July 2, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacological restoration of impaired autophagy in retinal ganglion cells prevents abnormal mitochondrial accumulation and glaucomatous neurodegeneration.

Molecular neurodegeneration·2026
Same author

Mechanistic Insights into Glucocorticoid-Induced Ocular Hypertension Using Differences in Mouse Strain Responsiveness.

The American journal of pathology·2025
Same author

Therapeutic mRNA delivery of CRISPR-Cas9 to the trabecular meshwork reverses ocular hypertension in myocilin glaucoma.

Molecular therapy. Methods & clinical development·2025
Same author

Biodistribution of Reconstituted High-Density Lipoprotein Nanoparticles for Targeted Delivery to Retinal Ganglion Cells.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2025
Same author

C/EBP Homologous Protein Expression in Retinal Ganglion Cells Induces Neurodegeneration in Mice.

International journal of molecular sciences·2025
Same author

Phenethylaminylation: Preliminary <i>In Vitro</i> Evidence for the Covalent Transamidation of Psychedelic Phenethylamines to Glial Proteins using 3,5-Dimethoxy-4-(2-Propynyloxy)-Phenethylamine as a Model Compound.

bioRxiv : the preprint server for biology·2025
Same journal

σ<sub>1</sub> receptor agonists: the new trend or an emerging therapeutic option?

Expert opinion on emerging drugs·2026
Same journal

Obefazimod (ABX464) for moderate-to-severe Crohn's disease: clinical development of a novel oral therapeutic approach.

Expert opinion on emerging drugs·2026
Same journal

Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease.

Expert opinion on emerging drugs·2026
Same journal

Emerging treatment options for chronic obstructive pulmonary disease: a look into 2026 and beyond.

Expert opinion on emerging drugs·2026
Same journal

Beyond triptans in menstrual migraine: the emerging role of CGRP-targeted therapies.

Expert opinion on emerging drugs·2026
Same journal

Acute management of adult MOG antibody-associated disease: therapeutic choices and clinical outcomes.

Expert opinion on emerging drugs·2026
See all related articles

Glaucoma, a leading cause of blindness, affects aging populations. New therapies aim to slow vision loss, but understanding disease pathways is key to reversing glaucomatous damage.

Area of Science:

  • Ophthalmology
  • Neuroscience

Background:

  • Glaucoma is a primary cause of irreversible blindness globally, with increasing prevalence due to aging populations.
  • Ocular hypertension is a significant risk factor, and current treatments focus on lowering intraocular pressure.
  • Existing therapies slow vision loss but do not halt or reverse the underlying disease processes.

Purpose of the Study:

  • To review current understanding of glaucoma pathophysiology and therapeutic strategies.
  • To highlight the need for novel treatments that intervene in or reverse glaucomatous damage.
  • To emphasize the necessity for improved diagnostic methods to detect glaucoma earlier.

Main Methods:

  • Review of current literature on glaucoma pathogenesis and treatment.
  • Analysis of existing and emerging therapeutic approaches, including ocular hypotensive and neuroprotective agents.

Related Experiment Videos

  • Discussion of advancements in understanding disease mechanisms and clinical measurement techniques.

    • Main Results:

    • Several new ocular hypotensive and neuroprotective agents offer varied treatment options.
    • Current treatments primarily slow disease progression rather than addressing root causes.
    • Significant progress has been made in understanding pathogenic pathways and measurement methods.

    Conclusions:

    • Further understanding of glaucoma pathophysiology is crucial for developing treatments that can intervene in or reverse vision damage.
    • Improved clinical methods are needed for earlier diagnosis, as significant damage often occurs before detection.
    • Future research should focus on disease-modifying therapies and enhanced diagnostic tools to combat glaucoma's impact.